680 results match your criteria Reviews in Endocrine and Metabolic Disorders [Journal]


Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?

Rev Endocr Metab Disord 2018 Dec;19(4):363-395

Institute of Diabetes ''Gerhardt Katsch'', Karlsburg, Germany.

The immune system is closely intertwined with the endocrine system. Many effects of medications used for various clinical endocrine conditions such as the metabolic syndrome, hypercholesterolemia, diabetes mellitus, hypertension, Graves' disease and others also have an impact on the immune system. Some drugs including statins, metformin, angiotensin converting enzyme and proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones are known to have immunomodulatory properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9478-8DOI Listing
December 2018
3 Reads

Immunoendocrinology: When (neuro)endocrinology and immunology meet.

Rev Endocr Metab Disord 2018 Dec;19(4):277-282

University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9479-7DOI Listing
December 2018
1 Read

Familial hyperaldosteronism type III a novel case and review of literature.

Rev Endocr Metab Disord 2018 Dec 19. Epub 2018 Dec 19.

Department of Pediatrics, Hospital Lluís Alcanyís de Xàtiva, Ctra. Xàtiva a Silla km 2, 46800, Xàtiva, Valencia, Spain.

Less than 15% of hypertension cases in children are secondary to a primary hyperaldosteronism. This is idiopathic in 60% of the cases, secondary to a unilateral adenoma in 30% and 10% remaining by primary adrenal hyperplasia, familial hyperaldosteronism, ectopic aldosterone production or adrenocortical carcinoma.To date, four types of familial hyperaldosteronism (FH I to FH IV) have been reported. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9481-0
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9481-0DOI Listing
December 2018
11 Reads

Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions.

Rev Endocr Metab Disord 2018 Dec;19(4):335-347

Medicover GmbH, Berlin/Hannover, Germany.

The pituitary gland and the hypothalamus can be affected by autoimmune-mediated structural and functional disruption. These autoimmune-mediated diseases occur more commonly in females and are often found during pregnancy or in the post-partum period. Autoimmune diseases can either affect parts of the pituitary or hypothalamus, or can involve both sellar and suprasellar structures. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9480-1
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9480-1DOI Listing
December 2018
12 Reads

Myo-inositol in autoimmune thyroiditis, and hypothyroidism.

Rev Endocr Metab Disord 2018 Dec;19(4):349-354

Department of Clinical and Experimental Medicine, University of Pisa, School of Medicine, Via Savi, 10, I-56126, Pisa, Italy.

Myo-inositol (Myo-Ins) plays an important role in thyroid function and autoimmunity. Myo-Ins is the precursor for the synthesis of phosphoinositides, which takes part in the phosphatidylinositol (PtdIns) signal transduction pathway, and plays a decisive role in several cellular processes. In the thyroid cells, PtdIns is involved in the intracellular thyroid-stimulating hormone (TSH) signaling, via Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) (PIP-3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9477-9DOI Listing
December 2018
2 Reads

The protective effect of myo-inositol on human thyrocytes.

Rev Endocr Metab Disord 2018 Dec;19(4):355-362

Department of Clinical and Experimental Medicine, University of Pisa, School of Medicine, Via Savi, 10, I-56126, Pisa, Italy.

Patients affected by autoimmune thyroiditis reached positive effects on indices of thyroid autoimmunity and/or thyroidal function, after following a treatment with selenomethionine (Se) alone, or Se in combination with Myo-inositol (Myo-Ins). Our purpose was to investigate if Myo-Ins alone, or a combination of Se + Myo-Ins, is effective in protecting thyroid cells from the effects given by cytokines, or hydrogen peroxide (HO). We assessed the interferon (IFN)-γ-inducible protein 10 (IP-10/CXCL10) secretion by stimulating primary thyrocytes (obtained from Hashimoto's thyroiditis or from control patients) with cytokines in presence/absence of HO Our results confirm: 1) the toxic effect of HO in primary thyrocytes that leads to an increase of the apoptosis, to a decrease of the proliferation, and to a slight reduction of cytokines-induced CXCL10 secretion; 2) the secretion of CXCL10 chemokine induced by IFN-γ + tumor necrosis factor alpha (TNF)-α has been decreased by Myo + Ins, both in presence or absence of HO; 3) no effect has been shown by the treatment with Se. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9476-x
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9476-xDOI Listing
December 2018
17 Reads

Endocrine disorders associated with hepatitis C virus chronic infection.

Rev Endocr Metab Disord 2018 Dec;19(4):397-403

Rheumatology Unit, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy.

The term "HCV syndrome" encompasses several organ- and systemic pathophysiological states, which often recognize autoimmunity or neoplastic evolution in their pathophysiology, as well as chronic HCV infection as trigger. The clinical features of HCV patients are heterogenous, and may include endocrine or metabolic disorders, namely autoimmune thyroiditis, type 2 diabetes mellitus, and erectile/sexual dysfunctions. In this review, we summarize current knowledge on the endocrine/metabolic diseases associated with chronic HCV infection, focusing on the main concepts emerged in the recent literature in this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9475-yDOI Listing
December 2018
2 Reads

The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Rev Endocr Metab Disord 2018 Dec;19(4):301-309

Department of Clinical and Experimental Medicine, University of Messina, Viale Gazzi, 98125, Messina, Italy.

Although the incidence of some malignancy has decreased over the recent years, this is not the case of papillary thyroid microcarcinoma (PTMC), whose incidence has increased worldwide. Most PTMC are found incidentally after histological examination of specimens from surgery for benign thyroid disease. Hashimoto's thyroiditis, whose incidence has also increased, coexists in about one in three PTMC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9474-zDOI Listing
December 2018
8 Reads

Gender dysphoria and transgender medicine in the year 2018.

Rev Endocr Metab Disord 2018 Sep;19(3):193-195

Division of Endocrinology, Metabolism and Lipids at Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9471-2DOI Listing
September 2018
1 Read

Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.

Rev Endocr Metab Disord 2018 Jun;19(2):107-109

ENDOC Center for Endocrine Tumors, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9472-1
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9472-1DOI Listing
June 2018
2 Reads

Black swans - neuroendocrine tumors of rare locations.

Rev Endocr Metab Disord 2018 Jun;19(2):111-121

ENDOC Center for Endocrine Tumors, Hamburg, Germany.

Neuroendocrine neoplasms (NEN) are rare and heterogeneous. Therefore, they often remain unrecognized for many years, causing significant disease burden. We here report on four unusual NEN presentations including a metastatic NEN of the kidney, hypoglycemia caused by an insulin-like growth factor-2-oma (previously called non-islet-cell tumor hypoglycemia), multifocal pheochromocytoma in von Hippel Lindau syndrome, and ileal NEN metastatic to the heart. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9473-0
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9473-0DOI Listing
June 2018
12 Reads

Somatostatin receptor expression in non-classical locations - clinical relevance?

Rev Endocr Metab Disord 2018 Jun;19(2):123-132

Division of Nuclear Medicine and Department of Radiology, University of Mississippi Medical Center, Jackson, MS, USA.

In-111 pentetreotide (Octreoscan) is a radiolabeled somatostatin analog with high binding affinity to somatostatin receptors (SSTR) used in somatostatin receptor scintigraphy (SRS). Pentetreotide labelled with In-111 is widely used due to its high affinity to SSTR 2 and 5. SSTR are expressed on neuroendocrine cells as well as several non-neural and non-endocrine cells with varying levels of density. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9470-3DOI Listing
June 2018
1 Read

Gut microbiota and Hashimoto's thyroiditis.

Rev Endocr Metab Disord 2018 Dec;19(4):293-300

Endocrinology Section, Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Latina, Italy.

About two third of the human microbial commensal community, namely the gut microbiota, is hosted by the gastrointestinal tract which represents the largest interface of the organism to the external environment. This microbial community co-evolved in a symbiotic relationship with the human beings. Growing evidence support the notion that the microbiota plays a significant role in maintaining nutritional, metabolic and immunologic homeostasis in the host. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9467-yDOI Listing
December 2018
5 Reads

Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Rev Endocr Metab Disord 2018 Jun;19(2):179-192

Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Avenida Menéndez Pidal s/n, Edificio IMIBIC, 14004, Córdoba, Spain.

Neuroendocrine tumors (NETs) comprise a complex and highly heterogeneous group of neoplasms that can arise all over the body, originating from neuroendocrine cells. NETs are characterized by a general lack of symptoms until they are in advanced phase, and early biomarkers are not as available and useful as required. Heterogeneity is an intrinsic, pivotal feature of NETs that derives from diverse causes and ultimately shapes tumor fate. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9465-0
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9465-0DOI Listing
June 2018
13 Reads

Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Rev Endocr Metab Disord 2018 Jun;19(2):169-178

Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.

The incidence of neuroendocrine tumors (NET) increases with age. Lately, the diagnosis of NET was mainly caused by early detection of small NET (<1 cm) in the rectum and stomach, which are depicted by chance during routine and prophylactic endoscopy. Also in patients with large and metastatic pancreatic and intestinal tumors thorough pathologic investigation with use of different immunohistologic markers discovers more neuroendocrine tumors with low differentiation grade (G2-G3) and more neuroendocrine carcinomas (NEC), nowadays, than in former times. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9469-9DOI Listing
June 2018
9 Reads

Nutrition and neuroendocrine tumors: An update of the literature.

Rev Endocr Metab Disord 2018 Jun;19(2):159-167

Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini 5, 82121, Naples, Italy.

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms with worldwide increasing incidence, high prevalence and survival. Both the tumor itself and the systemic therapy may have an impact on patients' nutrition. Malnutrition negatively impacts on outcome in NETs patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9466-z
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9466-zDOI Listing
June 2018
13 Reads

Is endoscopic ultrasonography more sensitive than magnetic resonance imaging in detecting and localizing pancreatic neuroendocrine tumors?

Rev Endocr Metab Disord 2018 Jun;19(2):133-137

Centre for Endocrinology, Diabetology & Osteology, Endocrine Laboratory, Philipp's University and University Hospital Marburg, Marburg, Germany.

To compare endoscopic ultrasonography (EUS) and magnetic resonance imaging (MRI) in terms of their sensitivities to localize pancreatic neuroendocrine tumors (pNET) preoperatively. Systematic analysis of the literature; sensitivity of EUS and MRI in insulinomas and pancreaticoduodenal NETs in multiple endocrine neoplasia type 1 (MEN1) in series of at least 20 subjects referring to tumors confirmed by surgery and histopathology. Other imaging methods reported were also assessed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9464-1
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9464-1DOI Listing
June 2018
13 Reads

Emerging topics in transgender medicine.

Authors:
Vin Tangpricha

Rev Endocr Metab Disord 2018 Sep;19(3):197-198

Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9468-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224302PMC
September 2018
10 Reads

Thyroid disorders induced by checkpoint inhibitors.

Rev Endocr Metab Disord 2018 Dec;19(4):325-333

Department of Clinical and Experimental Medicine, University of Pisa, School of Medicine, Via Savi, 10, I-56126, Pisa, Italy.

Immune checkpoint inhibitors are drugs that inhibit the "checkpoint molecules". Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab). The increased immune response induced by these agents leads to immune-related adverse events (irAEs), that can vary from mild to fatal, according to the organ system and severity. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9463-2
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9463-2DOI Listing
December 2018
13 Reads

Agreement between medical records and self-reports: Implications for transgender health research.

Rev Endocr Metab Disord 2018 Sep;19(3):263-269

Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, CNR 3021, Atlanta, GA, 30322, USA.

A key priority of transgender health research is the evaluation of long-term effects of gender affirmation treatment. Thus, accurate assessment of treatment receipt is critical. The data for this analysis came from an electronic medical records (EMR) based cohort of transgender individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9461-4DOI Listing
September 2018
3 Reads

Fertility preservation options in transgender people: A review.

Rev Endocr Metab Disord 2018 Sep;19(3):231-242

Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Gender affirming procedures adversely affect the reproductive potential of transgender people. Thus, fertility preservation options should be discussed with all transpeople before medical and surgical transition. In transwomen, semen cryopreservation is typically straightforward and widely available at fertility centers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9462-3
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9462-3DOI Listing
September 2018
9 Reads

Bone health in patients with inborn errors of metabolism.

Rev Endocr Metab Disord 2018 Mar;19(1):81-92

Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.

Inborn errors of metabolism encompass a wide spectrum of disorders, frequently affecting bone. The most important metabolic disorders that primarily influence calcium or phosphate balance, resulting in skeletal pathology, are hypophosphatemic rickets and hypophosphatasia. Conditions involving bone marrow or affecting skeletal growth and development are mainly the lysosomal storage disorders, in particular the mucopolysaccharidoses. Read More

View Article

Download full-text PDF

Source
https://www.researchgate.net/publication/327604755_Bone_heal
Web Search
http://link.springer.com/10.1007/s11154-018-9460-5
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9460-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208570PMC
March 2018
9 Reads

Impact of pregnancy on inborn errors of metabolism.

Authors:
Gisela Wilcox

Rev Endocr Metab Disord 2018 Mar;19(1):13-33

School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester, UK.

Once based mainly in paediatrics, inborn errors of metabolism (IEM), or inherited metabolic disorders (IMD) represent a growing adult medicine specialty. Individually rare these conditions have currently, a collective estimated prevalence of >1:800. Diagnosis has improved through expanded newborn screening programs, identification of potentially affected family members and greater awareness of symptomatic presentations in adolescence and in adulthood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9455-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208575PMC
March 2018
5 Reads

Transgender medicine- transitioning transgender children to adulthood.

Rev Endocr Metab Disord 2018 Sep;19(3):227-230

Department of Internal Medicine, Division of Endocrinology and Metabolism, UT Southwestern Medical Center, Dallas, TX, USA.

There has been an increasing prevalence of individuals presenting for treatment of gender dysphoria over the past several years. This growing population includes transgender children referred to pediatric clinics. Transgender children meeting diagnostic criteria for gender dysphoria, with supportive mental health care, may be treated with gonadotropin releasing hormone (GnRH) agonists and cross sex hormones. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9458-z
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9458-zDOI Listing
September 2018
28 Reads

Quality of life of treatment-seeking transgender adults: A systematic review and meta-analysis.

Rev Endocr Metab Disord 2018 Sep;19(3):199-220

Institute of Mental Health, Faculty of Medicine & Health Sciences, University of Nottingham, Room B12, B Floor, Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK.

The study aims to systematically extract and analyse data about Quality of Life (QoL) in the transgender population. A systematic literature search and meta-analysis were conducted using the MEDLINE, EMBASE, PubMed, and PsycINFO databases, up to July 2017. Only English language quantitative studies, in adults, which reported the means for validated QoL measures were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9459-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223813PMC
September 2018
1 Read

Transgender medicine - puberty suppression.

Rev Endocr Metab Disord 2018 Sep;19(3):221-225

Department of Pediatrics, Division of Pediatric Endocrinology, Emory University, 2nd floor, rm 456, 2015 Uppergate Drive NE, Atlanta, GA, 30322, USA.

Puberty suppression is the reversible first step of endocrine medical treatment in transgender youth, and allows for two very important aspects of transgender management. Firstly, it buys the patient, family and their medical team time to fully evaluate the presence and persistence of gender dysphoria. Secondly, it successfully prevents the development of cis-gender unwanted secondary sexual characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9457-0DOI Listing
September 2018
2 Reads

When zebras run with horses - inherited metabolic diseases come mainstream.

Rev Endocr Metab Disord 2018 Mar;19(1):1-3

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9456-1DOI Listing
March 2018
2 Reads

Cardiovascular health in transgender people.

Authors:
Michael S Irwig

Rev Endocr Metab Disord 2018 Sep;19(3):243-251

Center for Andrology and Division of Endocrinology, Medical Faculty Associates, The George Washington University, 2300 M St NW, Washington, DC, 20037, USA.

This review examines the relationship between exogenous sex steroids and cardiovascular events and surrogate markers in trans (transgender) people. Data from trans populations is compared to data from postmenopausal women and hypogonadal men when appropriate. In an age-adjusted comparison with cisgender people, trans people appear to have an increased risk for myocardial infarction and death due to cardiovascular disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9454-3DOI Listing
September 2018
19 Reads

Approach to the interpretation of unexpected laboratory results arising in the care of patients with inborn errors of metabolism (IEM).

Rev Endocr Metab Disord 2018 Mar;19(1):5-12

McMaster Health Sciences Centre, Hamilton, ON, Canada.

Endocrinologists may encounter abnormal results in routine laboratory tests while caring for patients with inborn errors of metabolism. This article provides a framework for understanding these abnormalities as: a) part of the pathophysiology of the exceptional disease, b) exceptional laboratory errors related to the exceptional disease, or c) routine laboratory errors to which any patient sample is susceptible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9453-4DOI Listing
March 2018
3 Reads

An overview of inborn errors of metabolism manifesting with primary adrenal insufficiency.

Rev Endocr Metab Disord 2018 Mar;19(1):53-67

Section on Endocrinology & Genetics, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Building 10, CRC, Room 1-3330, 10 Center Dr., MSC1103, Bethesda, MD, 20892, USA.

Primary adrenal insufficiency (PAI) results from an inability to produce adequate amounts of steroid hormones from the adrenal cortex. The most common causes of PAI are autoimmune adrenalitis (Addison's disease), infectious diseases, adrenalectomy, neoplasia, medications, and various rare genetic syndromes and inborn errors of metabolism that typically present in childhood although late-onset presentations are becoming increasingly recognized. The prevalence of PAI in Western countries is approximately 140 cases per million, with an incidence of 4 per 1,000,000 per year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9447-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204320PMC
March 2018
5 Reads

Thyroid diseases and skin autoimmunity.

Rev Endocr Metab Disord 2018 Dec;19(4):311-323

Department of Surgical Sciences, "Sapienza" University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy.

The skin is the largest organ of the body, at the boundary with the outside environment. Primarily, it provides a physical and chemical barrier against external insults, but it can act also as immune organ because it contains a whole host of immune-competent cells of both the innate and the adaptive immune systems, which cooperate in eliminating invading pathogens following tissue injury. On the other hand, improper skin immune responses lead to autoimmune skin diseases (AISD), such as pemphigus, bullous pemphigoid, vitiligo, and alopecia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9450-7DOI Listing
December 2018
4 Reads

Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.

Rev Endocr Metab Disord 2018 Mar;19(1):93-106

Dutch Fatty Acid Oxidation Expertise Center, Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Pediatrics, Emma Children's Hospital, Academic Medical Center, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.

Mitochondrial fatty acid oxidation is an essential pathway for energy production, especially during prolonged fasting and sub-maximal exercise. Long-chain fatty acids are the most abundant fatty acids in the human diet and in body stores, and more than 15 enzymes are involved in long-chain fatty acid oxidation. Pathogenic mutations in genes encoding these enzymes result in a long-chain fatty acid oxidation disorder in which the energy homeostasis is compromised and long-chain acylcarnitines accumulate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9448-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208583PMC
March 2018
22 Reads

Innate immune cells in the adipose tissue.

Rev Endocr Metab Disord 2018 Dec;19(4):283-292

Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.

Immune cells are present in the adipose tissue (AT) and regulate its function. Under lean conditions, immune cells predominantly of type 2 immunity, including eosinophils, M2-like anti-inflammatory macrophages and innate lymphoid cells 2, contribute to the maintenance of metabolic homeostasis within the AT. In the course of obesity, pro-inflammatory immune cells, such as M1-like macrophages, prevail in the AT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9451-6DOI Listing
December 2018
20 Reads

Endocrine treatment of aging transgender people.

Rev Endocr Metab Disord 2018 Sep;19(3):253-262

Department of Endocrinology and Center for Sexology and Gender Ghent University Hospital, Corneel Heymanslaan 10 9 K12, 9000, Ghent, IE, Belgium.

High quality empirical data assessing morbidity and mortality and cancer incidence among transgender people are almost non-existent. Sex hormone treatment of conditions in older non-transgender people might as yet be taken as the best available analogy to hormone administration to aging transgender persons. Testosterone administration to transgender men carries little risk with regard to cardiovascular disease and cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9449-0DOI Listing
September 2018
13 Reads

Gaps in transgender medical education among healthcare providers: A major barrier to care for transgender persons.

Rev Endocr Metab Disord 2018 Sep;19(3):271-275

Center for Transgender Medicine and Surgery, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, 275 7th Ave, Suite 1505, New York, NY, 10001, USA.

A lack of access to knowledgeable providers is the greatest reported barrier to care for transgender individuals. The purpose of this manuscript is to review the recent literature characterizing transgender medicine education for medical providers and to summarize effective interventions for improving education in transgender care. The PubMed database was searched for all literature that assessed transgender medical education among physicians or trainees and all papers that reported results of transgender-specific educational interventions. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-018-9452-5
Publisher Site
http://dx.doi.org/10.1007/s11154-018-9452-5DOI Listing
September 2018
14 Reads

Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes.

Rev Endocr Metab Disord 2018 Mar;19(1):35-52

Institute of Cellular Medicine (Diabetes), The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

Diabetes mellitus is a heterogeneous group of conditions defined by resultant chronic hyperglycemia. Given the increasing prevalence of diabetes mellitus and the increasing understanding of genetic etiologies, we present a broad review of rare genetic forms of diabetes that have differing diagnostic and/or treatment implications from type 1 and type 2 diabetes. Advances in understanding the genotype-phenotype associations in these rare forms of diabetes offer clinically available examples of evolving precision medicine where defining the correct genetic etiology can radically alter treatment approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9446-3DOI Listing
March 2018
1 Read

How should incidental NEN of the pancreas and gastrointestinal tract be followed?

Rev Endocr Metab Disord 2018 Jun;19(2):139-144

Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, "Vita-Salute" University, Via Olgettina 60, 20132, Milan, Italy.

Neuroendocrine gastro-entero-pancreatic neoplasms (GEP-NENs) constitute a heterogeneous group of tumors, whose incidence has increased over the years. The most frequent site for primary disease is the stomach followed by small and large intestine, and pancreas. In the last decade, a dramatic growing in the incidence of small, incidental GEP-NENs has been recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9445-4DOI Listing
June 2018
4 Reads

Hyperammonemia and lactic acidosis in adults: Differential diagnoses with a focus on inborn errors of metabolism.

Authors:
Michel Tchan

Rev Endocr Metab Disord 2018 Mar;19(1):69-79

Department of Genetic Medicine, Westmead Hospital, Westmead, NSW, Australia.

The adult endocrinologist may be asked to consult on a patient for unexplained biochemical disturbances that could be caused by an underlying inborn error of metabolism. A genetic disorder is generally less likely to be the cause as these disorders are individually rare, however inborn errors of metabolism are collectively not infrequent and important to consider as they may be treatable and tragic outcomes avoided. Hyperammonemia or lactic acidosis are most often secondary markers of an acquired primary disease process, but they may be a clue to the presence of a genetic disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9444-5DOI Listing
March 2018
7 Reads

Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Rev Endocr Metab Disord 2017 12;18(4):373-378

Medicover Oldenburg MVZ, Oldenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9442-7DOI Listing
December 2017
6 Reads

Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Rev Endocr Metab Disord 2018 Jun;19(2):145-158

Department of Internal Medicine IV, University-Hospital Campus Grosshadern, Ludwig-Maximilian University of Munich, Munich, Germany.

Neuroendocrine tumors (NETs) are a group of rare and heterogeneous malignancies that can develop in various organs. A significant number of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is functionally active and presents with symptoms related to the secretion of biologically active substances, leading to the development of distinct clinical syndromes. There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional therapies as well as systemic therapeutic options including peptide receptor radionuclide therapy, cytotoxic therapy, and molecularly targeted therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9443-6DOI Listing
June 2018
4 Reads

Editorial : Neuroendocrine neoplasms.

Rev Endocr Metab Disord 2017 Dec;18(4):379-380

ENDOC Center, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-018-9441-8DOI Listing
December 2017
2 Reads

The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.

Rev Endocr Metab Disord 2017 Dec;18(4):473-483

Gastrointestinal Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori (National Cancer Institute), Via Venezian 1, 20133, Milan, Italy.

Liver metastases occur in nearly half of NET patients (MNETs) and heavily affect prognosis, with 5-yr. OS around 19-38%. Although it is difficult to show outcome differences for available treatments, due to the long course of disease, surgery for MNETs remains the most effective option in terms of survival and symptom control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9439-7DOI Listing
December 2017
6 Reads

Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Rev Endocr Metab Disord 2018 Dec;19(4):405-420

Department of Clinical and Experimental Medicine, School of Medicine, University of Pisa, Via Savi 10, I-56126, Pisa, Italy.

Type 2 diabetes mellitus (T2DM) is an endocrine disorder encompassing multifactorial mechanisms, and chronic hepatitis C virus infection (CHC) is a multifaceted disorder, associated with extrahepatic manifestations, including endocrinological disorders. CHC and T2DM are associated, but the subject remains controversial. We performed a systematic review and meta-analysis evaluating such association, searching on PubMed until February 29, 2016. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11154-017-9440-1
Publisher Site
http://dx.doi.org/10.1007/s11154-017-9440-1DOI Listing
December 2018
16 Reads

Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

Rev Endocr Metab Disord 2017 12;18(4):393-410

Schwerpunkt Endokrinologie und Stoffwechselerkrankungen, I. Medizinischen Klinik und Poliklinik; ENETS center of excellence, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstrasse 1, 55101, Mainz, Germany.

Neuroendocrine neoplasms of the digestive system (GEP-NEN) represent a heterogeneous group of malignancies with various clinical presentation and prognosis. GEP-NENs can potentially affect all organs of the gastrointestinal tract; characteristically they share the biological property to produce and secrete peptides and neuroamines. About 30% of GEP-NENs are hormonally active and can cause specific clinical syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9438-8DOI Listing
December 2017
14 Reads

Management of neuroendocrine tumors of unknown primary.

Rev Endocr Metab Disord 2017 Dec;18(4):423-431

Division of Endocrinology, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Neuroendocrine neoplams (NENs) are mostly relatively indolent malignancies but a significant number have metastatic disease at diagnosis mainly to the liver. Although in the majority of such cases the primary origin of the tumor can be identified, in approximately 11-22% no primary tumor is found and such cases are designated as NENs of unknown primary origin (UPO). This has significant therapeutic implications with respect to potentially resectable hepatic disease and/or application of appropriate medical therapy, either chemotherapeutic agents or targeted treatment, as the response to various treatments varies according to the origin of the primary tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9437-9DOI Listing
December 2017
8 Reads

Is there any role for minimally invasive surgery in NET?

Rev Endocr Metab Disord 2017 Dec;18(4):443-457

Section of Endocrine Surgery, Department of General, Visceral and Thoracic Surgery, Academic Teaching Hospital University of Hamburg, Reinbek, Germany.

Neuroendocrine tumors (NET) represent the variability of almost benign lesions either secreting hormones occurring as a single lesion up to malignant lesions with metastatic potential. Treatment of NET is usually performed by surgical resection. Due to the rarity of NET, surgical treatment is mainly based on the experience and recommendations of experts and less on the basis of prospective randomized studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9436-xDOI Listing
December 2017
6 Reads

Correction to: X-linked hypophosphatemia and growth.

Rev Endocr Metab Disord 2017 Nov 7. Epub 2017 Nov 7.

Division of Pediatrics, Department of Medicine, Faculty of Medicine, University of Oviedo, Oviedo, Asturias, Spain.

The authors of the article would like to note an error in the acknowledgements section of this paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9435-yDOI Listing
November 2017
5 Reads

Echocardiography in functional midgut neuroendocrine tumors: When and how often.

Rev Endocr Metab Disord 2017 Dec;18(4):411-421

Department of Cardiovascular Surgery, Mount Sinai Health System, The Mount Sinai Hospital, 1190 Fifth Avenue, GP2 West, New York, NY, 10029-6574, USA.

The management of patients with midgut neuroendocrine tumors (MNET) is rapidly evolving. Current preoperative detection rates of primary tumor sites are higher than ever and progression-free survival in patients with already advanced disease is expanding due to the implementation of novel efficacious treatment strategies. This survival benefit may potentially translate into a need for a multidisciplinary approach to an even more heterogenous variety of clinical conditions, among these, carcinoid syndrome (CS) and carcinoid heart disease (CHD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9434-zDOI Listing
December 2017
16 Reads

Liver transarterial embolizations in metastatic neuroendocrine tumors.

Rev Endocr Metab Disord 2017 Dec;18(4):459-471

Department of Gastroenterology and Pancreatology, DHU UNITY, ENETS Center of Excellence, Beaujon Hospital (APHP), Paris-Diderot University, 100 boulevard du Général Leclerc, 92110, Clichy, France.

The management of patients with well-differentiated neuroendocrine tumors (NET) and non-resectable liver metastases is challenging. Liver-directed transarterial embolization (TAE), transarterial chemo-embolization (TACE) and selective internal radiation therapy (SIRT) have a place of choice among other treatment modalities. However, their utilization relies on a low level of proof, due to the lack of prospective data, the absence of comparative studies and considerable heterogeneity between local practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9431-2DOI Listing
December 2017
17 Reads

When should genetic testing be performed in patients with neuroendocrine tumours?

Rev Endocr Metab Disord 2017 12;18(4):499-515

Centre of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Neuroendocrine tumours (NETs) are a heterogenous group of tumours arising from neuroendocrine cells in several sites around the body. They include tumours of the gastroenteropancreatic system, phaeochromocytoma and paraganglioma and medullary thyroid cancer. In recent years, it has become increasingly apparent that a number of these tumours arise as a result of germline genetic mutations and are inherited in an autosomal dominant pattern. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11154-017-9430-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849652PMC
December 2017
32 Reads